Management

Chris Chapman, M.D. serves as an appointed a director for MIRA Pharmaceuticals Inc. Prior to joining MIRA Pharmaceuticals Inc., and since 2015, Dr. Chapman serves as the current President, Chief Medical Officer and Director of MyMD Pharmaceuticals, Inc., and since 1999, Dr. Chapman has also served as the Chief Executive Officer of Chapman Pharmaceutical Consulting, Inc., a consulting organization that provides support to pharmaceutical and biotech companies in North America, Europe, Japan, India and Africa on issues such as product safety, pharmacovigilance, medical devices, clinical trials and regulatory issues. In addition, from 2003-2004, Dr. Chapman served as the Associate Director of Drug Safety, Pharmacovigilance, and Clinical Operations for Organon Pharmaceuticals, where he was responsible for the supervision of four fellow M.D.s and 10 drug safety specialists.

Prior to his time at Organon, Dr. Chapman served as Director, Medical Affairs, Drug Safety and Medical Writing Departments at Quintiles (currently known as IQVIA), from 1995-2003, where he grew the division from no employees to forty employees, including eight board certified physicians, four RNs, two pharmacists, eight medical writers and supporting staff. Dr. Chapman has also served on the board of directors of Rock Creek Pharmaceuticals, Inc. (f/k/a Star Scientific, Inc.) from 2007-2016, including as a member of the Audit Committee from 2007-2014, chairperson of the Compensation Committee from 2007-2014, and chairperson of the Executive Search Committee from 2007 to 2014. Dr. Chapman is an experienced executive and global medical expert, and has extensive experience in providing monitoring and oversight for ongoing clinical trials including both adult and pediatric subjects.

Dr. Chapman is also the founder of the Chapman Pharmaceutical Health Foundation, an IRS Section 501(c)(3) nonprofit organization established to solicit public funds and to support healthcare needs such as AIDS, diabetes, hypertension, lupus, sickle cell anemia, malaria and tuberculosis, which was organized in 2006. Dr. Chapman is a graduate of the Harvard Kennedy School of Cambridge, Massachusetts for financial management in 2020. Dr. Chapman received his M.D. degree from Georgetown University in Washington, D.C. in 1987, and completed his internship in Internal Medicine, a residency in Anesthesiology and a fellowship in Cardiovascular and Obstetric Anesthesiology at Georgetown. Prior to his time at Georgetown, Dr. Chapman served in the air force as a B-52 crew chief in the Vietnam era.

Michelle Yanez, MBA, joined our Company as Chief Financial Officer in June 2024. Ms. Yanez is a senior financial executive with over 25 years of experience in public and privately held biotech, pharmaceutical, and life science companies. Ms. Yanez’ experience includes a broad range of responsibilities in a highly complex and regulated market. She also brings deep corporate governance experience through her work with corporate boards, including audit, compensation, nominating & governance and finance committees. Ms. Yanez’ serves as the Chief Financial Officer of MIRA Pharmaceuticals (NASDAQ: MIRA) since April 2023, which is a publicly traded pre-clinical-stage pharmaceutical development company with neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. Ms. Yanez joined MIRA in April 2022 as a Corporate Controller. Since May 2024, Ms. Yanez has served as the President of Telomir International, a privately held pre-clinical-stage pharmaceutical company focused on international opportunities. From May 2002 until its acquisition in April 2022, Ms. Yanez held various leadership positions at BioDelivery Sciences International, Inc. (NASDAQ: BDSI). In her role, she led financial offerings, managed due diligence for product acquisitions and financings and managed finance documents and filings for the tender offer, leading to the acquisition of BioDelivery Sciences in April 2022. Ms. Yanez also serves as a non-employee director of Inhibitor Therapeutics, Inc. (OTCQB: INTI), a publicly traded pharmaceutical development company focused on therapeutics for certain cancers and non-cancerous proliferation disorders, since December 2022. Ms. Yanez is also Co-Founder and Chief Financial Officer of Santander Pharma Consulting, a privately held life sciences consulting firm that provides business development and commercial strategy services to pharmaceutical, medical device, and life science companies offering guidance throughout all stages of commercial development, from inception to product launch, since February 2024.

Ms. Yanez earned her B.A. in Business Management from University South Florida and further distinguished her acumen with an MBA in Strategic Leadership from Rutgers School of Business, Cum Laude.

Dr O’Donnell is our scientific advisor. As such he is part of the team that is responsible for strategy, direction, and execution of the Company’s clinical development plans. In addition, he works with senior management to evaluate the scientific, and clinical viability of potential products, assessing their commercial potential to address unmet medical indications taking into account approved drugs as well as drugs under development by competitors. Dr. O’Donnell has thirty years of experience in pharmaceutical development.

He received his BA from Johns Hopkins University’s accelerated program and his MD from Johns Hopkins University School of Medicine, as well as his specialty and fellowship training. He is an inventor or co-inventor on over 40 US patents.